Media headlines about Mallinckrodt PLC (NYSE:MNK) have trended somewhat positive on Saturday, according to Accern. Accern ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mallinckrodt PLC earned a news impact score of 0.09 on Accern’s scale. Accern also gave media stories about the company an impact score of 47.2533869537188 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Mallinckrodt PLC (MNK) opened at 36.52 on Friday. Mallinckrodt PLC has a 1-year low of $36.02 and a 1-year high of $85.83. The firm’s market capitalization is $3.55 billion. The firm’s 50-day moving average price is $43.88 and its 200 day moving average price is $45.56.

Mallinckrodt PLC (NYSE:MNK) last released its earnings results on Tuesday, August 8th. The company reported $1.85 earnings per share for the quarter, beating analysts’ consensus estimates of $1.73 by $0.12. The firm had revenue of $824.50 million during the quarter, compared to the consensus estimate of $829.56 million. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The company’s revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the company posted $2.03 EPS. On average, analysts predict that Mallinckrodt PLC will post $7.48 EPS for the current year.

Several equities research analysts have recently weighed in on MNK shares. Jefferies Group LLC reissued a “buy” rating and issued a $70.00 price objective on shares of Mallinckrodt PLC in a research report on Tuesday, June 20th. Morgan Stanley set a $65.00 price objective on Mallinckrodt PLC and gave the company a “buy” rating in a research report on Wednesday, May 31st. Deutsche Bank AG set a $68.00 price objective on Mallinckrodt PLC and gave the company a “buy” rating in a research report on Wednesday, May 31st. Mizuho reissued a “buy” rating and issued a $73.00 price objective on shares of Mallinckrodt PLC in a research report on Wednesday, May 31st. Finally, UBS AG set a $70.00 price objective on Mallinckrodt PLC and gave the company a “buy” rating in a research report on Wednesday, May 24th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and sixteen have issued a buy rating to the company’s stock. Mallinckrodt PLC presently has a consensus rating of “Buy” and an average price target of $72.44.

TRADEMARK VIOLATION NOTICE: “Mallinckrodt PLC (NYSE:MNK) Given Media Impact Rating of 0.09” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/mallinckrodt-plc-nysemnk-given-media-impact-rating-of-0-09/1477629.html.

In related news, VP Coleman N. Lannum III bought 1,350 shares of the business’s stock in a transaction dated Friday, June 2nd. The stock was purchased at an average cost of $42.89 per share, for a total transaction of $57,901.50. Following the transaction, the vice president now owns 30,955 shares in the company, valued at approximately $1,327,659.95. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Hugh M. O’neill bought 1,000 shares of the business’s stock in a transaction dated Thursday, June 8th. The shares were bought at an average price of $40.24 per share, with a total value of $40,240.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 3,850 shares of company stock valued at $157,687. Corporate insiders own 0.77% of the company’s stock.

Mallinckrodt PLC Company Profile

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Insider Buying and Selling by Quarter for Mallinckrodt PLC (NYSE:MNK)

Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.